 Englewood Cliffs NJ, July 07, 2021 GLOBE NEWSWIRE -- Silo Pharma, Inc. OTC QB: SILO, a developmental stage biopharmaceutical company, today announced that it has extended its exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as Joint-homing peptides for use in the investigation and treatment of arthritogenic processes. 